GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Q2 FY27 Investor Presentation Highlights FDF Transition

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 11:41 AM IST  ·  BSE ID: 1b5618a9-3145-4614-be9e-bf802ed38880
View Original BSE Filing (PDF)
💡
In Simple Terms
Ind-Swift Laboratories shared a presentation highlighting its Q2 FY27 results, showing strong revenue and profit growth after shifting to a new business focus.
🤖 AI Summary
  • Ind-Swift Laboratories released an investor presentation on its unaudited financial results for the quarter ended September 30, 2026 (Q2 FY27).
  • Q2 FY27 operating income increased over 50% year-on-year, driven by a strategic transition to a Finished Dosage Formulation (FDF) manufacturer.
  • Operating EBITDA margin expanded to 18.02% and PAT margin reached 13.21% in Q2 FY27, reflecting a stronger business model.
  • H1 FY27 operating revenue stood at ₹420.97 crore, showing a 35.79% increase, with operating EBITDA growing more than 4x.
  • The company maintains a net-debt-free balance sheet and plans a ₹250 crore capex program funded by internal accruals.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Q2 FY27 Operating Income Growth
over 50%
Q2 FY27 Operating EBITDA Margin
18.02%
Q2 FY27 PAT Margin
13.21%
H1 FY27 Operating Revenue
₹420.97 crore
35.79%
H1 FY27 Operating EBITDA Growth
more than 4x
Capex Programme
₹250 crore
🏢 How This Affects the Company
📈
Business Impact
The company's strategic exit from the API and CRAMS business via a ₹1,650 crore slump sale to Synthimed Labs Pvt. Ltd. repositions it as a pure-play Finished Dosage Formulation (FDF) company. This shift is supporting deeper own-brand penetration in key export markets and an ongoing EU-GMP upgrade.
💰
Financial Impact
The proceeds from the ₹1,650 crore slump sale were used to repay the entire external debt, transitioning the balance sheet to net debt-free with substantial cash and investments. This enables funding of a ₹250 crore capex program through internal accruals.
⚙️
Operational Impact
Ind-Swift Limited merged into Ind-Swift Laboratories Limited (effective 31 March 2024), consolidating into a single, streamlined, formulation-focused entity. The company operates manufacturing units in Derabassi, Punjab, and Samba, J&K, with the Samba facility focused on 100% export.
⚠️
Risk Impact
The strategic exit from capital-intensive API operations and debt elimination reduces financial leverage risk. The company's focus on a compliance-led FDF platform with accreditations like UK-MHRA and Health Canada supports market access and regulatory standing.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this investor presentation filing.
👤
Who Is Affected
Shareholders are provided an update on the company's financial performance for Q2 & H1 FY27, highlighting growth in operating income and margins, and its net debt-free status.
🔍
Management Signal
Management's commentary emphasizes the success of its strategic shift from an API to a focused FDF manufacturer and commitment to funding growth through internal accruals.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check if revenue and margin growth sustain.
Updates on Samba EU-GMP upgrade progress and timeline.
Details on the ₹250 crore capex program deployment and impact.
LOW RISK The filing reports positive financial performance and a net-debt-free balance sheet, reducing immediate financial risks.
💡 Investor Takeaway
Ind-Swift Laboratories reported Q2 FY27 operating income growth of over 50% year-on-year, with operating EBITDA margin reaching 18.02% and PAT margin 13.21%. H1 FY27 operating revenue increased 35.79% to ₹420.97 crore, confirming the impact of its FDF transition and debt-free balance sheet.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 operating income grew over 50% year-on-year, demonstrating revenue scale-up from core operations.
  • Operating EBITDA margin expanded to 18.02% and PAT margin to 13.21% in Q2 FY27, indicating improved profitability and business model strength.
📅 Company Track Record
Ind-Swift Laboratories' Q2 FY27 operating income rose over 50.15% to ₹234.89 crore, with PAT up 3.54x, as per prior filings. The company previously reported a Q2 FY27 standalone net profit increase of 254.33% to Rs. 3102.82 Lakhs. These results follow a board meeting on October 29, 2026, to approve the Q2 financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Ind-Swift Laboratories' Q2 FY27 operating income and margin figures?
Ind-Swift Laboratories reported Q2 FY27 operating income growth of over 50% year-on-year, with an operating EBITDA margin of 18.02% and a PAT margin of 13.21%.
What is Ind-Swift Laboratories' H1 FY27 operating revenue?
Ind-Swift Laboratories' H1 FY27 operating revenue stood at ₹420.97 crore, representing a 35.79% increase from the prior period.
How has Ind-Swift Laboratories' balance sheet changed?
The company has transitioned to a net-debt-free balance sheet following the use of ₹1,650 crore from the API & CRAMS business slump sale to repay external debt.
What is Ind-Swift Laboratories' planned capital expenditure?
Ind-Swift Laboratories has a ₹250 crore capex program that will be funded through internal accruals.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.